IMR Press / CEOG / Volume 37 / Issue 3 / pii/1630630220617-817933407

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Evidence that high serum progesterone (P) levels on day of human chorionic gonadotropin (hCG) injection have no adverse effect on the embryo itself as determined by pregnancy outcome following embryo transfer using donated eggs
Show Less
1 The University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2010, 37(3), 179–180;
Published: 10 September 2010
Abstract

Purpose: To determine if too high of a level of progesterone at the time of peak follicular maturation of donors adversely affects pregnancy or implantation rates of recipients. Methods: A retrospective cohort analysis was performed on donor egg recipients. Pregnancy rates were calculated according to ranges of five serum progesterone (P) levels based on two standard deviations before and above the mean. Results: No adverse effect was found in recipients whose donors had serum P levels between 2.47 and 3.41 ng/ml. There may have been a slightly lower pregnancy rate in recipients whose donors had seen P levels over 3.41 but there were only seven patients in that group and there still was a live delivered pregnancy rate of 28.6% per transfer. Conclusions: The main adverse effect of a premature rise of progesterone in women making multiple follicles with gonadotropin stimulation seems to be on the endometrium. There appear to be enough follicles not affected by the progesterone to recommend proceeding with oocyte retrieval in the donor so as not to waste money on expensive medication and monitoring.
Keywords
Serum progesterone
Late follicular phase
Oocyte donor
Recipients
Share
Back to top